Fibroma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (15 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Fibroma}} | |||
{{CMG}}{{AE}} {{M.N}} | |||
==overview== | ==overview== | ||
Medical therapy depends on the type of fibroma. | The majority treatment of cases of fibromas is not medical therapy, but for some one's such as [[uterine fibroma]] does have [[medical]] therapy.[[Medical]] therapy depends on the type of fibroma. | ||
==Medical therapy== | ==Medical therapy== | ||
The majority treatment of cases of fibromas is not medical therapy, but for some one's such as [[uterine fibroma]] does have [[medical]] therapy.<ref name="SabryAl-Hendy2012">{{cite journal|last1=Sabry|first1=Mohamed|last2=Al-Hendy|first2=Ayman|title=Medical Treatment of Uterine Leiomyoma|journal=Reproductive Sciences|volume=19|issue=4|year=2012|pages=339–353|issn=1933-7191|doi=10.1177/1933719111432867}}</ref><ref name="DonnezDolmans2016">{{cite journal|last1=Donnez|first1=Jacques|last2=Dolmans|first2=Marie-Madeleine|title=Uterine fibroid management: from the present to the future|journal=Human Reproduction Update|volume=22|issue=6|year=2016|pages=665–686|issn=1355-4786|doi=10.1093/humupd/dmw023}}</ref><ref name="MurjiWhitaker2017">{{cite journal|last1=Murji|first1=Ally|last2=Whitaker|first2=Lucy|last3=Chow|first3=Tiffany L|last4=Sobel|first4=Mara L|title=Selective progesterone receptor modulators (SPRMs) for uterine fibroids|journal=Cochrane Database of Systematic Reviews|year=2017|issn=14651858|doi=10.1002/14651858.CD010770.pub2}}</ref><ref name="ArenaZupi2011">{{cite journal|last1=Arena|first1=Saverio|last2=Zupi|first2=Errico|title=Heavy Menstrual Bleeding: Considering the Most Effective Treatment Option|journal=Women's Health|volume=7|issue=2|year=2011|pages=143–146|issn=1745-5065|doi=10.2217/WHE.11.1}}</ref><ref name="De LeoMorgante2002">{{cite journal|last1=De Leo|first1=Vincenzo|last2=Morgante|first2=Giuseppe|last3=La Marca|first3=Antonio|last4=Musacchio|first4=Maria Concetta|last5=Sorace|first5=Massimo|last6=Cavicchioli|first6=Chiara|last7=Petraglia|first7=Felice|title=A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas|journal=Drug Safety|volume=25|issue=11|year=2002|pages=759–779|issn=0114-5916|doi=10.2165/00002018-200225110-00002}}</ref><ref name="SankaranManyonda2008">{{cite journal|last1=Sankaran|first1=Srividhya|last2=Manyonda|first2=Isaac T.|title=Medical management of fibroids|journal=Best Practice & Research Clinical Obstetrics & Gynaecology|volume=22|issue=4|year=2008|pages=655–676|issn=15216934|doi=10.1016/j.bpobgyn.2008.03.001}}</ref><ref name="Palomba2002">{{cite journal|last1=Palomba|first1=S.|title=Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial|journal=Human Reproduction|volume=17|issue=12|year=2002|pages=3213–3219|issn=14602350|doi=10.1093/humrep/17.12.3213}}</ref><ref name="Golan1996">{{cite journal|last1=Golan|first1=A.|title=GnRH analogues in the treatment of uterine fibroids|journal=Human Reproduction|volume=11|issue=suppl 3|year=1996|pages=33–41|issn=0268-1161|doi=10.1093/humrep/11.suppl_3.33}}</ref> | |||
===Uterine fibroma=== | ===Uterine fibroma=== | ||
At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor. | * At present, there are no definitive agents for long-term [[medical treatment]] of [[uterine fibroma]] approved by [[Food and Drug Administration]] (FDA). But however, there are some agents that can be used in the management of this common [[benign tumor]].<ref name="SabryAl-Hendy2012">{{cite journal|last1=Sabry|first1=Mohamed|last2=Al-Hendy|first2=Ayman|title=Medical Treatment of Uterine Leiomyoma|journal=Reproductive Sciences|volume=19|issue=4|year=2012|pages=339–353|issn=1933-7191|doi=10.1177/1933719111432867}}</ref><ref name="DonnezDolmans2016">{{cite journal|last1=Donnez|first1=Jacques|last2=Dolmans|first2=Marie-Madeleine|title=Uterine fibroid management: from the present to the future|journal=Human Reproduction Update|volume=22|issue=6|year=2016|pages=665–686|issn=1355-4786|doi=10.1093/humupd/dmw023}}</ref><ref name="MurjiWhitaker2017">{{cite journal|last1=Murji|first1=Ally|last2=Whitaker|first2=Lucy|last3=Chow|first3=Tiffany L|last4=Sobel|first4=Mara L|title=Selective progesterone receptor modulators (SPRMs) for uterine fibroids|journal=Cochrane Database of Systematic Reviews|year=2017|issn=14651858|doi=10.1002/14651858.CD010770.pub2}}</ref><ref name="ArenaZupi2011">{{cite journal|last1=Arena|first1=Saverio|last2=Zupi|first2=Errico|title=Heavy Menstrual Bleeding: Considering the Most Effective Treatment Option|journal=Women's Health|volume=7|issue=2|year=2011|pages=143–146|issn=1745-5065|doi=10.2217/WHE.11.1}}</ref><ref name="De LeoMorgante2002">{{cite journal|last1=De Leo|first1=Vincenzo|last2=Morgante|first2=Giuseppe|last3=La Marca|first3=Antonio|last4=Musacchio|first4=Maria Concetta|last5=Sorace|first5=Massimo|last6=Cavicchioli|first6=Chiara|last7=Petraglia|first7=Felice|title=A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas|journal=Drug Safety|volume=25|issue=11|year=2002|pages=759–779|issn=0114-5916|doi=10.2165/00002018-200225110-00002}}</ref><ref name="SankaranManyonda2008">{{cite journal|last1=Sankaran|first1=Srividhya|last2=Manyonda|first2=Isaac T.|title=Medical management of fibroids|journal=Best Practice & Research Clinical Obstetrics & Gynaecology|volume=22|issue=4|year=2008|pages=655–676|issn=15216934|doi=10.1016/j.bpobgyn.2008.03.001}}</ref><ref name="Palomba2002">{{cite journal|last1=Palomba|first1=S.|title=Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial|journal=Human Reproduction|volume=17|issue=12|year=2002|pages=3213–3219|issn=14602350|doi=10.1093/humrep/17.12.3213}}</ref><ref name="Golan1996">{{cite journal|last1=Golan|first1=A.|title=GnRH analogues in the treatment of uterine fibroids|journal=Human Reproduction|volume=11|issue=suppl 3|year=1996|pages=33–41|issn=0268-1161|doi=10.1093/humrep/11.suppl_3.33}}</ref> | ||
====Gonadotropin-Releasing Hormone Analogues==== | |||
*[[Gonadotropin-releasing hormone analogue|Gonadotropin-releasing hormone analogues]] can effectively reduce [[uterine leiomyoma]] volume, [[menorrhagia]](heavy [[menstrual bleeding]]), and also stabilize [[hemoglobin]] levels by inducing an [[iatrogenic]] reversible [[menopause]]. | |||
*Some of them are [[Leuprolide]], [[Buserelin]], [[Nafarelin]], [[Deslorelin]], [[Histrelin]], [[Goserelin]], Tryptorelin | |||
*Effects of [[Gonadotropin-releasing hormone agonist|GnRH agonists]] are temporary, and re-growth has been reported in many cases of leiomyomas to their pretreatment sizes after stopping them. | |||
====GnRH analogues With Add-Back Therapy==== | |||
*Commonly used add-back agents are [[progestins]] alone, [[estrogen]] alone, combined [[estrogen]] and [[progesterone]], [[tibolone]], and [[raloxifene]]. | |||
*To overcome the unwanted [[side effects]] and maintaining the benefits of [[GnRH]] therapy add-back therapy is commonly used. | |||
==References== | |||
{{reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Gynecology]] | |||
[[Category:Types of cancer]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
Latest revision as of 17:17, 18 September 2019
|
Fibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fibroma medical therapy On the Web |
|
American Roentgen Ray Society Images of Fibroma medical therapy |
|
Risk calculators and risk factors for Fibroma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2]
overview
The majority treatment of cases of fibromas is not medical therapy, but for some one's such as uterine fibroma does have medical therapy.Medical therapy depends on the type of fibroma.
Medical therapy
The majority treatment of cases of fibromas is not medical therapy, but for some one's such as uterine fibroma does have medical therapy.[1][2][3][4][5][6][7][8]
Uterine fibroma
- At present, there are no definitive agents for long-term medical treatment of uterine fibroma approved by Food and Drug Administration (FDA). But however, there are some agents that can be used in the management of this common benign tumor.[1][2][3][4][5][6][7][8]
Gonadotropin-Releasing Hormone Analogues
- Gonadotropin-releasing hormone analogues can effectively reduce uterine leiomyoma volume, menorrhagia(heavy menstrual bleeding), and also stabilize hemoglobin levels by inducing an iatrogenic reversible menopause.
- Some of them are Leuprolide, Buserelin, Nafarelin, Deslorelin, Histrelin, Goserelin, Tryptorelin
- Effects of GnRH agonists are temporary, and re-growth has been reported in many cases of leiomyomas to their pretreatment sizes after stopping them.
GnRH analogues With Add-Back Therapy
- Commonly used add-back agents are progestins alone, estrogen alone, combined estrogen and progesterone, tibolone, and raloxifene.
- To overcome the unwanted side effects and maintaining the benefits of GnRH therapy add-back therapy is commonly used.
References
- ↑ 1.0 1.1 Sabry, Mohamed; Al-Hendy, Ayman (2012). "Medical Treatment of Uterine Leiomyoma". Reproductive Sciences. 19 (4): 339–353. doi:10.1177/1933719111432867. ISSN 1933-7191.
- ↑ 2.0 2.1 Donnez, Jacques; Dolmans, Marie-Madeleine (2016). "Uterine fibroid management: from the present to the future". Human Reproduction Update. 22 (6): 665–686. doi:10.1093/humupd/dmw023. ISSN 1355-4786.
- ↑ 3.0 3.1 Murji, Ally; Whitaker, Lucy; Chow, Tiffany L; Sobel, Mara L (2017). "Selective progesterone receptor modulators (SPRMs) for uterine fibroids". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010770.pub2. ISSN 1465-1858.
- ↑ 4.0 4.1 Arena, Saverio; Zupi, Errico (2011). "Heavy Menstrual Bleeding: Considering the Most Effective Treatment Option". Women's Health. 7 (2): 143–146. doi:10.2217/WHE.11.1. ISSN 1745-5065.
- ↑ 5.0 5.1 De Leo, Vincenzo; Morgante, Giuseppe; La Marca, Antonio; Musacchio, Maria Concetta; Sorace, Massimo; Cavicchioli, Chiara; Petraglia, Felice (2002). "A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas". Drug Safety. 25 (11): 759–779. doi:10.2165/00002018-200225110-00002. ISSN 0114-5916.
- ↑ 6.0 6.1 Sankaran, Srividhya; Manyonda, Isaac T. (2008). "Medical management of fibroids". Best Practice & Research Clinical Obstetrics & Gynaecology. 22 (4): 655–676. doi:10.1016/j.bpobgyn.2008.03.001. ISSN 1521-6934.
- ↑ 7.0 7.1 Palomba, S. (2002). "Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial". Human Reproduction. 17 (12): 3213–3219. doi:10.1093/humrep/17.12.3213. ISSN 1460-2350.
- ↑ 8.0 8.1 Golan, A. (1996). "GnRH analogues in the treatment of uterine fibroids". Human Reproduction. 11 (suppl 3): 33–41. doi:10.1093/humrep/11.suppl_3.33. ISSN 0268-1161.